ClinicalTrials.gg

Post-Acute COVID-19 Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 605 studies for Post-Acute COVID-19 Syndrome across more than 10 countries. 201 are recruiting or about to start. 500 of them are mainly about Post-Acute COVID-19 Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

ClinicalTrials.gov finds 713 studies for Post-Acute COVID-19 Syndrome. How that becomes 604 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Post-Acute COVID-19 Syndrome, and those it files under no condition that list Post-Acute COVID-19 Syndromethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 713Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −3List Post-Acute COVID-19 Syndrome as a condition, but the registry did not file them under itMost often written as “Long COVID Syndrome” (2) and “Long COVID Fatigue” (1). The registry filed them under other conditions only, most often Myocarditis (1) and Heart Failure (1).
  3. −106Match it another way41 name it in the title, 3 in a keyword, and 62 by a synonym or other text the search reads.
  4. 604The count on this page5 of them list Post-Acute COVID-19 Syndrome in their own words; the registry filed them under no condition.

Status

Completed
272
Recruiting
145
Status unknown
51
Active, not recruiting
49
Not yet recruiting
43
Withdrawn
14

Phase

Phase 2
94
Phase 3
34
Phase 1
14
Phase 4
10
Early Phase 1
6

Where

United States
194
Spain
52
Germany
41
Canada
40
Italy
29
United Kingdom
27

Who develops what

Add Post-Acute COVID-19 Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 7 with this as their studies’ main aim; 2 with a live phase 3 study; 4 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
MaravirocApproved: US · EU 2007☆ Track1 live phase-3 study: NCT06974084HealthBio, Inc.
REGENECYTE☆ Track1 live phase-3 study: NCT07184385StemCyte, Inc.

The 2 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Dec 2026 est.Maraviroc · HealthBio, Inc. · Phase 3 main aimNCT06974084 A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID — primary endpoint: Fatigue · 252 enrolled
  • Mar 2027 est.nogapendekin alfa inbakicept · ImmunityBio, Inc. · Phase 2 main aimNCT07123727 A Study to Examine Anktiva for the Treatment of COVID-19. — primary endpoint: Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration. · 40 enrolled
  • Jun 2027 est.ibramvibart · Invivyd, Inc. · Phase 2 main aimNCT07899346 Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome — primary endpoint: Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90 · 130 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Post-Acute COVID-19 Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · JAK inhibitors 2 open · Corticosteroids 1 open · Stimulants 3

Coming up

57studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger. 15 (10%) take children under 18. 2 (1%) are for women only and 0 (0%) for men only; 39 (27%) take healthy volunteers.

Recruiting studies that take each age, of 145
AgeWomenMen
1012 (8%)12 (8%)
18134 (92%)132 (91%)
30136 (94%)134 (92%)
40137 (94%)135 (93%)
50139 (96%)137 (94%)
65133 (92%)132 (91%)
7597 (67%)97 (67%)
8579 (54%)79 (54%)

Across all 605 studies, recruiting or not: 35% stop at 75 or younger and 24% at 65; 8% take children; 1% are for women only and <1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Post-Acute COVID-19 Syndrome studies take

Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 217 mo12–23 · 63 studies—17 mo12–24 · 46 studies
Interventional, no phase16 mo7–27 · 244 studies—16 mo8–28 · 233 studies
Observational27 mo14–39 · 104 studies—27 mo17–39 · 97 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 605. Browse all 605 → or search them.